Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 11/20 | 0.48 |
| ▸ | CCR3 | P51677 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16467581 | 0.89 | PTPRB (0.46) | PTPRBCCR3RAB9AMEN1KMT2A | |
| SCHEMBL3606140 | 0.84 | PTPRB (0.58) | PTPRBCCR3MEN1KMT2A | |
| SCHEMBL3606138 | 0.84 | PTPRB (0.58) | PTPRBCCR3MEN1KMT2A | |
| SCHEMBL28828126 | 0.83 | PTPRB (0.49) | PTPRBCCR3 | |
| SCHEMBL679207 | 0.81 | PTPRB (0.50) | PTPRBCCR3GAARAB9AMEN1 | |
| SCHEMBL684486 | 0.80 | PTPRB (0.73) | PTPRBCTSK | |
| SCHEMBL8522780 | 0.78 | PTPRB (0.46) | PTPRBCCR3GAARAB9AMEN1 | |
| SCHEMBL16030965 | 0.76 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL16030968 | 0.76 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL27240709 | 0.76 | PTPRB (0.61) | PTPRBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885CCR3 1918/4885GAA 2308/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885CCR3 112/4885GAA 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.